Carol Abraham appointed to Patient Engagement Collaborative

Today, the U.S. Food and Drug Administration (FDA), in collaboration with the Clinical Trials Transformation Initiative (CTTI), announced that Carol Abraham has been appointed to the Patient Engagement Collaborative (PEC) and will serve a two year term. Carol is the Coalition to Cure Calpain 3 Director of Community Outreach and the founder of the LGMD Awareness Foundation. Carol was selected from more than 100 applications.

The PEC, established in 2018, is a group of patient organizations and individual members who discuss ways to enhance patient engagement and incorporate the patient voice in the FDA’s medical regulatory programs. CTTI and the FDA collaborate to involve members with a variety of perspectives including patients, caregivers and members from diverse patient organizations.

As a PEC member, Carol will be involved in continuing the dialogue around how patient perspectives can inform and enhance the clinical trials community.

Read the Official FDA Announcement here.